Eli Lilly signs R&D pact with Canadian pharmaceutical company

Indianapolis-based Eli Lilly and Co. announced Thursday that it has signed a research and collaboration agreement with Edmonton, Alberta-based Entos Pharmaceuticals that grants Lilly exclusive rights to the Canadian company’s delivery system. for nucleic acid therapies.

Entos will receive an upfront payment of $50 million as part of the deal, which includes an equity stake in Entos by Lilly. For each program under the agreement, Entos could also receive up to $400 million in potential milestone payments, as well as royalties, for successful product development and commercialization.

Lilly said the agreement would support the development of therapies for multiple neurological conditions.

Exclusive rights to Entos’ nucleic acid delivery technology, Fusogenix, will allow Lilly to research, develop and commercialize products that would target the central and peripheral nervous system.

“Nucleic acid therapies hold great promise for addressing the biological cause of many serious diseases that have significant unmet medical needs,” said Andrew Adams, vice president of Lilly Genetic Medicine, in written remarks. “Overcoming barriers to the safe and effective delivery of such therapies to specific target cells is critical to realizing their potential. We look forward to working with Entos as we work to overcome this challenge and develop potential new therapies that can improve patient outcomes. »

Comments are closed.